Kim, & Blakeney, ). Experiences of case managers in providing. ; (2), KIM MS et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. . Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN B, SENAN S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. , & Reijneveld, S. Quality of life. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kumar,. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiother. Planning of radiotherapy capacity and productivity. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, van Tinteren H, Praag JO, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Oncol. Radiobiological. (). J Thorac Oncol. Stereotactic Slotman B, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF.